Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Dec 05, 2007 7:30am EST

Rigel Announces Presentations at the 2007 American Society of Hematology (ASH) Meeting

Nov 21, 2007 2:40pm EST

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP

Nov 14, 2007 7:30am EST

Merck Serono Exercises Option to Rigel's R763/AS703569 and Aurora Kinase Inhibitors in the Japanese Territory

Nov 09, 2007 11:40am EST

Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study

Nov 06, 2007 7:30am EST

Rigel Announces Third Quarter 2007 Financial Results

Oct 30, 2007 7:30am EDT

Rigel Announces Presentations at Upcoming Investor and Partnering Conferences

Oct 16, 2007 7:30am EDT

Rigel to Present Research Programs at Scientific Conferences

Aug 28, 2007 7:30am EDT

Rigel Announces Presentations at Two Investor Conferences

Aug 07, 2007 7:30am EDT

Rigel Announces Second Quarter 2007 Financial Results

Jul 12, 2007 7:30am EDT

Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies

  • Previous
  • 1…
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin